A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
Goldman, Jonathan W, Mazieres, Julien, Barlesi, Fabrice, Dragnev, Konstantin H, Koczywas, Marianna, Göskel, Tuncay, Cortot, Alexis B, Girard, Nicolas, Wesseler, Claas, Bischoff, Helge, Nadal, Ernest, Park, Keunchil, Lu, Shun, Taus, Alvaro, Cobo, Manuel, Estrem, Shawn T, Wijayawardana, Sameera R, Turner, Kellie, Oakley, 3rd, Gerard Joseph, Hurt, Karla C, Chiang, Alan Y, Hossain, Anwar M, John, William J, Paz-Ares, Luis
Published in Frontiers in oncology (26.10.2020)
Published in Frontiers in oncology (26.10.2020)
Get full text
Journal Article